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Research
Arsenic is a worldwide water contaminant,
and chronic exposure has been associated
with a large number of health effects, such as
different forms of cancer, skin lesions, vascu-
lar diseases, liver- and neurotoxicity, and dia-
betes mellitus [Internal Agency for Research
on Cancer 2004; World Health Organization
(WHO) 2001]. A wide variation in suscepti-
bility to various health effects has been
reported (National Research Council 2001),
which, in part, may be due to the marked
variation in the metabolism of arsenic
(Vahter 2002). 
The classical pathway for the metabolism
of inorganic arsenic (iAs) involves alternating
reduction and oxidative methylation with
only one end product, dimethylarsinate
[DMA(V)] (Vahter 2002). Another—newly
proposed—pathway suggests methylation of
arsenic–glutathione complexes (Hayakawa
et al. 2005) or arsenic bound to proteins
(Naranmandura et al. 2006) with methyl-
arsonate [MA(V)] and DMA(V) as end prod-
ucts. Both pathways involve methylation of
arsenic via one-carbon metabolism with
S-adenosyl methionine (SAM) as the methyl
donor and requiring reduced glutathione
(GSH) (Figure 1). GSH and probably other
thiols serve as electron donors in the reduc-
tion reactions (Delnomdedieu et al. 1994a,
1994b; Scott et al. 1993), which are catalyzed
by reductases. 
Following exposure to iAs by ingestion or
inhalation, DMA(V) is the major metabolite
found in urine in most mammals, including
humans, but MA(V) is found in human
urine and very rarely in urine of other mam-
mals (Vahter 2002). The metabolism of iAs
involves both detoxification (methylation)
and activation (reduction). Although MA(V)
and DMA(V) have a lower toxicity than
inorganic arsenic species (Hughes and
Kenyon 1998), the trivalent methylated
metabolites are more reactive and toxic than
the other arsenic metabolites (Kligerman and
Tennant 2006; Petrick et al. 2000;
Schwerdtle et al. 2003a, 2003b; Styblo et al.
2000; Vega et al. 2001). A series of studies
reported the presence of methylarsonite
[MA(III)] and dimethylarsinite [DMA(III)]
in urine (Aposhian et al. 2000; Le et al.
2000; Mandal et al. 2001; Valenzuela et al.
2005), although high concentrations are not
likely to be found in urine because the high
reactivity renders them to bind in tissues
(Vahter 2002). In contrast, it is reasonable to
assume that the total amount of MA in urine
reflects the formation of the highly toxic
MA(III) in the body. This might explain the
observed increasing prevalence of arsenic-
related toxic effects (e.g., skin lesions, skin
cancer, bladder cancer, chromosome aberra-
tions) with an increasing percentage of MA
in urine (Chen et al. 2003a, 2003b, 2005;
Del Razo et al. 1997; Hsueh et al. 1997;
Maki-Paakkanen J 1998; Steinmaus et al.
2006; Yu et al. 2000). Furthermore, experi-
mental animals, most of which methylate
arsenic efficiently to DMA with essentially
no MA excretion, show a faster overall excre-
tion of arsenic than humans (Vahter 2002).
Also, people with a small percentage of uri-
nary arsenic as MA show less retention of
arsenic than those with a higher percentage
of urinary MA (Vahter 1999). 
Thus, it is essential to determine the rea-
sons for the marked variation in the metabo-
lism of arsenic between individuals and
population groups. One reason could be
genetic polymorphisms in the regulation of
enzymes involved in arsenic metabolism
(Vahter 2000). One arsenic-reductase has
been identiﬁed to be glutathione-S-transferase
omega (GSTO1), which is able to reduce
both MA(V) to MA(III) and arsenate [As(V)]
to arsenite [As(III)] (Zakharyan et al. 2001).
Recently, a SAM-dependent arsenic methyl-
transferase isolated in rat was found to be a
homolog of human arsenic (+III) methyl-
transferase (AS3MT; previously called Cyt19)
(Lin et al. 2002). Enzymes involved in the
one-carbon metabolism could also indirectly
influence the metabolism of arsenic, for
example, methylenetetrahydrofolate reductase
(MTHFR) (Figure 1). 
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BACKGROUND: There is a wide variation in susceptibility to health effects of arsenic, which, in part,
may be due to differences in arsenic metabolism. Arsenic is metabolized by reduction and methyla-
tion reactions, catalyzed by reductases and methyltransferases.
OBJECTIVES: Our goal in this study was to elucidate the influence of various demographic and
genetic factors on the metabolism of arsenic.
METHODS: We studied 415 individuals from Hungary, Romania, and Slovakia by measuring
arsenic metabolites in urine using liquid chromatography with hydride generation and inductively
coupled plasma mass spectrometry (HPLC-HG-ICPMS). We performed genotyping of arsenic
(+III) methyltransferase (AS3MT), glutathione S-transferase omega 1 (GSTO1), and methylene-
tetrahydrofolate reductase (MTHFR).
RESULTS: The results show that the M287T (T→C) polymorphism in the AS3MT gene, the
A222V (C→T) polymorphism in the MTHFR gene, body mass index, and sex are major factors
that inﬂuence arsenic metabolism in this population, with a median of 8.0 µg/L arsenic in urine.
Females < 60 years of age had, in general, higher methylation efﬁciency than males, indicating an
inﬂuence of sex steroids. That might also explain the observed better methylation in overweight or
obese women, compared with normal weight men. The influence of the M287T (T→C) poly-
morphism in the AS3MT gene on the methylation capacity was much more pronounced in men
than in women. 
CONCLUSIONS: The factors investigated explained almost 20% of the variation seen in the metabo-
lism of arsenic among men and only around 4% of the variation among women. The rest of the
variation is probably explained by other methyltransferases backing up the methylation of arsenic. 
KEY WORDS: arsenic, AS3MT, blood, GSTO1, methylation, MTHFR, polymorphisms, sex, urine.
Environ Health Perspect 115:1081–1086 (2007). doi:10.1289/ehp.10026 available via
http://dx.doi.org/ [Online 27 March 2007]Our aim in the present study was to eluci-
date the reasons for intraindividual variation
in arsenic metabolism. Therefore, we studied
the influence of age, sex, body mass index
(BMI), genetic polymorphisms, and selenium
status on the arsenic metabolite pattern
in urine. 
Materials and Methods
Study population. This study is part of a
case–control study concerning cancer risks in
relation to low-level arsenic exposure via
drinking water in Central Europe: Arsenic
Health Risk Assessment and Molecular
Epidemiology (ASHRAM). Study areas were
deﬁned as certain counties in Hungary (Bacs,
Békés, Csongrad, and Jazs-Nagykun-
Szolnok), Romania (Bihor and Arad), and
Slovakia (Banská Bystrica and Nitra) with
known hotspots of arsenic in drinking water.
The recruitment of skin, bladder, and kidney
cancer cases and hospital-based controls with
appendicitis, abdominal hernias, duodenal
ulcer, cholelithiasis, and fractures, as well as
the methods for collecting urine and blood
samples, are described elswhere (Lindberg
et al. 2006; Thirumaran et al. 2006). In
short, all spot urine samples and whole blood
samples, in spite of country, were collected
and stored at –20°C and –80°C, respectively,
until analysis. Informed consent was obtained
from all participants, and the study was
approved by the ethics committee of each
hospital. In order to eliminate any potential
bias caused by cancer, we selected controls
for evaluation of factors that influence the
metabolism of iAs.
There was a cluster of values close to
100% DMA at the lowest water arsenic con-
centrations. The intercept between the sum of
urinary arsenic metabolites plotted against cur-
rent water concentration was 2.5 μg/L, indi-
cating a significant contribution of arsenic
from food at the low exposure levels (Lindberg
et al. 2006). Also, when performing speciation
analysis in urine samples with very low
concentrations, it is often only the major
species that is above the limit of detection,
leading to nearly 100% DMA in this case.
Because of the inﬂuence of food and analyti-
cal precision on the percentage of DMA
(%DMA) in the low concentration range, we
decided to evaluate factors that inﬂuence the
metabolite pattern only at concentrations
> 2 μg/L, at which the influence from food
was less obvious. Furthermore, 11 individuals
were also excluded because they had high uri-
nary arsenic concentrations and low water
arsenic concentrations in combination with a
high percentage of DMA in the urine, indi-
cating a signiﬁcant contribution to the expo-
sure via food. The sample size after these
exclusions was 415 individuals.
Determination of arsenic compounds
with HPLC-HG-ICPMS. The arsenic
metabolites in urine were measured by an
inductively coupled plasma mass spectrome-
ter (ICPMS; HP 4500 or Agilent 7500cs;
Agilent Technologies, Waldbronn, Germany)
equipped with an integrated sample intro-
ducion system and a hydride generation
(HG) accessory together with an Agilent
1100 chromatographic system equipped with
solvent degasser, autosampler, and a ther-
mostatted column. The method is described
in more detail elswhere (Lindberg et al.
2006). We adjusted the arsenic concentra-
tions in urine to the average specific gravity
in the population (1.017 g/cm3) using a
refractometer (Leica TS 400 Refractometer;
Leica Microsystems Inc., Buffalo, NY, USA)
to compensate for variation in dilution. 
Determination of selenium in blood.
Selenium in whole blood was analyzed at a
commercial laboratory (Analytica AB, Luleå,
Sweden) with an inductively coupled plasma
sector field mass spectrometer (ELEMENT,
ThermoElectron; Finnigan MAT, Bremen,
Germany) monitoring m/z 78 in high-resolu-
tion mode (delta m/m = 11,000). Samples
were prepared by 25-fold dilution with
ammonia:Triton X:EDTA:ethanol mixture
(2%:0.0005%:0.0005%:4%) with addition
of arsenic at 10 ng/mL for internal standardi-
zation. Calibration was performed externally
with matrix-matched standards. Accuracy and
Lindberg et al.
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Table 1. Primers and probes used for SNP genotyping, including primer sequences, annealing temperatures, and fragment sizes of the ampliﬁed products used
for PCR ampliﬁcation and direct DNA sequencing.
Temp Size
Gene Primers (5´→3´) Probes (5´→3´) Primer sequence (°C) (bp)
MTHFR A222V (C→T)  F: GCACTTGAAGGAGAAGGTGTCT VIC: ATGAAATCGGCTCCCGC F: 5´-GAGGCTGACCTGAAGCACTTG-3´ 60 200
R: CCTCAAAGAAAAGCTGCGTGATG FAM: ATGAAATCGACTCCCG R: 5´-GTGGGGTGGAGGGAGCTTAT-3´
MTHFR E429A (A→C) F: GGAGGAGCTGCTGAAGATGTG VIC: ACCAGTGAAGAAAGTGT F: 5´-ATTCCTCTTCCCCTGCCTTTG-3´ 59 198
R: TGGTTCTCCCGAGAGGTAAAGA FAM: CAGTGAAGCAAGTGT R: 5´-TCCCCACTCCAGCATCACTC-3´
GSTO1 A140D (C→A) F: GCCATCCTTGGTAGGAAGCTTTATT VIC: AGAAGACTATGCTGGCCTA F: 5´-GGGGGCCGATACAGTTAGC-3´ 55 379
R: TCGTTTACTCTGATGATAGCTAGGAGAAA FAM: TAAAGAAGACTATGATGGCCTA R: 5´-AGCAAGCCCATGACAAAGTCT-3´
AS3MT M287T (T→C) F: AATGGAGGAATTACAGGACATGAAAAAGA VIC: ATTGGCATCAAACGTTAGT F: 5´-GAGTGCTGGAGATGAACCGTGA-3´ 56 231
R: AGAAAGAATACCAGAAGTCATGGAAATTGT FAM: TGGCATCAAACATTAGT R: 5´-GGGCAAGAGCAGAAAGAATACCAGA-3´
Abbreviations: F, forward; R, reverse; Temp, temperature,
Figure 1. The methionine and folic acid cycles and the metabolic pathway of arsenic. Abbreviations:
5-CH3-THF, methyl tetrahydrofolate; 5,10-CH2-THF, methylenetetrahydrofolate; As3MT, arsenic (+3 oxidation
state) methyltransferase; B2, vitamin B2 (riboﬂavin); B6, vitamin B6; CH3-B12, methylated vitamin B12; DHF,
dihydrofolate; DMG, dimethylglycine; GSTO1, glutathione-S-transferase omega; HCy, homocysteine; SAHCy,
S-adenosyl homocysteine; THF, tetrahydrofolate; Zn, zinc. 
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analysis of a commercial reference material
(Seronorm SN ok0336; SERO AS, Billingstad,
Norway).
Genotyping. DNA was isolated from
blood samples from both cases and controls
using Qiagen mini-preparation kits (Qiagen
GmbH, Hilden, Germany) and genotyped for
single nucleotide polymorphisms (SNPs) in
the following genes: MTHFR (Unigene acces-
sion no. Hs.214142; National Center for
Biotechnology Information 2007), GSTO1
(Hs.190028), and AS3MT (Hs.34492). The
SNPs selected for the analysis were non-
synonymous with a minor allele frequency of
at least 10%. We performed genotyping using
the 5´ nuclease allelic discrimination assay
(TaqMan) in 96-well format, as described
previously (Thirumaran et al. 2006). TaqMan
primers and probes were purchased from
Applied Biosystems (Foster City, CA, USA)
as “Assays-by-Design.” Primer and probe
sequences used for genotyping are shown in
Table 1. Polymerase chain reaction (PCR)
was performed in a 5–10 μL volume reaction
using 5 ng DNA as template, premade master
mix, and 0.5× probe–primer mix. The initial
temperature conditions for PCR were set at
50°C for 2 min and 95°C for 10 min, fol-
lowed by 35–40 cycles at 92°C for 15 sec and
60°C for 1 min. Genotyping on amplified
PCR products was scored by differences in
fluorescent levels of VIC and FAM (both
from Applied Biosystems) in plates read on an
ABI PRISM 7900HT sequence detection sys-
tem using SDS 1.2 software (Applied
Biosystems). Postoperation data were trans-
ferred as Microsoft Excel data (Microsoft
Corporation, Redmond, WA, USA) and con-
verted into genotype information.
Direct DNA sequencing. We randomly
veriﬁed 4% of genotyping results from allelic
discrimination assays by direct DNA sequenc-
ing. The sequencing reactions were performed
using the BigDyeR Terminator Cycle sequenc-
ing kit (Applied Biosystems) in a 10-mL vol-
ume containing PCR product pretreated with
ExoSapIT (Amersham Biosciences, Uppsala,
Sweden) and a sequencing primer (Table 1).
The temperature conditions set for sequenc-
ing reactions were 96°C for 2 min followed
by 27 cycles at 96°C for 30 sec, 54°C for
10 sec, and 60°C for 4 min. Sequencing
reaction products were precipitated with
2-propanol, washed with 75% ethanol, resus-
pended in 25 mL water, and loaded onto an
ABI Prism 3100 Genetic Analyzer (Applied
Biosystems). Primary sequencing data were
analyzed using a sequence analysis program
(Applied Biosystems).
Statistical analyses. To evaluate whether
selection in favor of a specific genotype had
occurred, we assessed the Hardy-Wienberg
equilibrium using allele frequencies. Statistica
7.1 for Windows (StatSoft Inc., Tulsa, OK,
USA) was used to perform the statistical
analyses. In the multivariate analyses using
linear regression, the variables were natural
log (ln)-transformed as needed to meet the
requirement of equal variance and normal
distribution of residuals. We used Spearman
correlation (rs) when testing for univariate
associations between continuous variables.
Nonparametric tests (Mann-Whitney U-test
and Kruskal-Wallis test) were used in testing
for univariate differences between groups. We
used one-way analysis of variance when test-
ing for univariate differences between geno-
types and Pearson chi-square when testing for
differences between categorical variables. The
multiple regression models, including all indi-
viduals, included variables that were signifi-
cantly associated with any of the relative
proportions of arsenic metabolites in the uni-
variate tests. The multiple regression models
stratified by sex included the variables that
were significantly associated with any of the
proportions of arsenic metabolites in the mul-
tiple regression models, including all individ-
uals. Tests for collinearity were performed
using tolerance. We included BMI in the
models instead of body surface area (BSA)
because BMI gave a higher coefficient of
determination (R2) compared with BSA.
When testing for differences in subgroups
(except sex), we used analysis of covariance
with dichotomized independent variables
[age, above a mean of 60 years or < 60 years;
BMI, > 25 kg/m2 and < 25 kg/m2, the limit
of overweight deﬁned by the WHO (2000)]
adjusted for continuous covariates that were
signiﬁcant in the multiple regression analyses
that included all individuals. We generally
used p < 0.05 to indicate statistical signifi-
cance, except p < 0.10 was used for some
interactions.
Results
Descriptive. The characteristics of the partici-
pants are shown in Table 2. A total of
225 males and 190 females, 60 years of age on
average, were included in the study. Twenty
percent were current smokers (26% of the
men and 14% of the women; p < 0.001). The
current smokers were younger (mean age,
53 years) than ex-smokers and nonsmokers
(mean age, 62 years and 65 years, respectively;
p < 0.001). Of the participants, 83% had
consumed any kind of alcohol (95% of the
men and 70% of the women; p < 0.001). The
average BMI and BSA were 27 kg/m2 and
1.9 m2, respectively. We found a positive cor-
relation between selenium in whole blood and
urinary arsenic (p < 0.001). The main reason
for this correlation was that the individuals
from Hungary had both higher urinary
arsenic concentrations and higher blood
selenium concentrations than individuals
form Romania and Slovakia. Among the
Hungarians, Romanians, or Slovakians,
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Table 2. Participant characteristics, data on exposure, proportions of urinary arsenic species and genotype
frequencies.
10–90th 
No. Percent Median percentile
Sex (male/female) 415 54/46
Smoking (never/former/current) 415 48/31/20
Alcohol use (yes/no) 412 83/17
BMI (normal/overweight/obese)a 414 35/40/25 27 21–34
BSAb 414 1.9 1.6–2.1
Age (years) 415 61 44–75
Urinary arsenic (µg/L)c 415 8.0 2.7–38
%DMA 415 73 59–86
%MA 415 17 8.2–27
%iAs 415 8.3 2.4–19
Selenium in blood (µg/L) 377 99  74–126
MTHFR A222V (C→T)
CC 181 44
CT 190 46
TT 43 10
MTHFR E429A (A→C)
AA 176 43
AC 186 45
CC 52 13
GST01 A140D (C→A)
CC 182 44
CA 190 46
AA 42 10
As3MT M287T (T→C)
TT 324 79
TC 84 20
CC 3 1
aCalculated as body weight (kg)/height (m)2; normal, 18.5–25 kg/m2; overweight, 25–30 kg/m2; obese, > 30 kg/m2. bCalculated
as body weight (kg)0.425 × height (cm)0.725 × 0.007184 (DuBois and DuBois 1916). cSum of iAs, MA, and DMA in urine.analyzed separately, we found no association
between arsenic and selenium concentrations.
The average proportions of iAs (%iAs), MA
(%MA), and DMA (%DMA) in urine were
8.3%, 17%, and 73%, respectively (Table 2).
However, there were wide variations. We
were able to detect traces of MA(III) in only
two samples (0.23 and 0.25 μg/L, respec-
tively) corresponding to 0.89 and 6.6% of the
total arsenic metabolites. The allele and geno-
type frequencies for the A222V (C→T)
MTHFR, E429A (A→C) MTHFR, A140D
(C→A) GSTO1, and M287T (T→C) AS3MT
polymorphisms are shown in Table 2. The
genotype distributions for all polymorphisms
were in accordance with the Hardy-Weinberg
distribution. Only three individuals were
homozygous for the variant allele in the
AS3MT gene and were therefore combined
with the heterozygotes for further analyses.
Genotype distributions were not associated
with sex or country. 
Univariate analyses. Men had higher
%iAs (p = 0.04) and %MA (p = 0.003),
and lower %DMA (p = 0.008) than women.
BMI was negatively associated with %MA
(p = 0.001) and positively associated with
%DMA (p = 0.003), but it was not associated
with %iAs. Blood selenium was positively
associated with %MA (p < 0.001) and nega-
tively associated with %DMA (p = 0.007),
but not with %iAs. Individuals homozygous
for the variant allele for the A222V (C→T)
MTHFR polymorphisms had lower %DMA
(p = 0.002) and higher %MA than individu-
als homozygous for the wild-type allele
(p = 0.01; Figure 2). Individuals heterozygous
and homozygous for the variant allele in the
M287T (T→C) AS3MT polymorphism had
lower %DMA (p = 0.003) and higher %MA
(p < 0.001; Figure 2). The concentration of
total urinary arsenic, smoking, or alcohol
use were not associated with %iAs, %MA,
or %DMA.
Multivariate analyses. We designed one
model for each arsenic metabolite. Table 3
shows the results of the multiple regression
analyses to test whether the distributions of
urinary arsenic metabolites were dependent on
sex, age, BMI, selenium, and gene polymor-
phisms in MTHFR, GSTO1, and AS3MT.
Similar to the univariate assessment, %DMA
was associated with polymorphisms in
AS3MT and MTHFR genes, selenium, BMI,
and sex in decreasing order. The %MA was
associated with a gene polymorphism in
AS3MT, selenium, BMI, sex, and a gene poly-
morphism in MTHFR in decreasing order.
However, for %iAs the multivariate analyses
showed only an association with sex and an
almost signiﬁcant association with a polymor-
phism in the MTHFR gene. For %MA, we
found a signiﬁcant interaction between BMI
(two categories: > 25 kg/m2 and below
< 25 kg/m2) and selenium (two categories:
above the median of 99 μg/L and > 99 μg/L;
p = 0.06). Also, the corresponding interaction
for %DMA was near signiﬁcance (p = 0.10). 
To better understand the difference
in methylation capacity between males
and females, we repeated the multiple regres-
sion analyses stratiﬁed by sex (Table 4). The
sex-speciﬁc models show that selenium, BMI,
and AS3MT polymorphisms affect the distrib-
ution of urinary arsenic metabolites in males,
but not in females. Also, in males, mutation in
one allele in the MTHFR gene altered the pat-
tern of urinary arsenic metabolites; however,
for females, mutations of both alleles were
required. Furthermore, to test whether the sex
difference in methylation capacity was depen-
dent on age or BMI, we used analysis of
covariance. In those < 60 years of age, males
had a higher %MA than females, but this was
not the case for those > 60 years of age
(Figure 3A). Furthermore, men of normal
weight had a higher %MA than overweight or
obese women (Figure 3B).
Discussion
The results of the present study show that the
M287T (T→C) polymorphism in the
AS3MT gene, the A222V (C→T) poly-
morphism in the MTHFR gene, BMI, and
sex are major factors that influence arsenic
metabolism in this Central European popula-
tion. This is the ﬁrst study to our knowledge
to elucidate factors influencing the metabo-
lism of iAs at these low concentrations, where
the influence of arsenic exposure on the
methylation reactions is negligible. It is also
the first to study arsenic-related polymor-
phisms in Europe. 
We found the allele frequencies to be in
accordance with those in other Caucasian
populations, but different from those in sev-
eral other populations (PharmGKB 2007a,
2007b, 2007c, 2007d). In contrast to our
ﬁnding that carriers of the variant allele of the
M287T (C→T) polymorphism of the
AS3MT gene had higher %MA, previous
studies in Mexico (Meza et al. 2005) and
Argentina (Schläwicke Engström et al. 2006)
have shown other SNPs in AS3MT gene to be
associated with lower %MA. However, we
did not ﬁnd those SNPs in the present study.
Thus, different SNPs in this gene influence
the metabolism of iAs in different directions.
It is unlikely that AS3MT is the only methyl-
transferase that methylates arsenic, given that
there are around 100 different methyltrans-
ferases identiﬁed in the human body (Martin
and McMillan 2002). This is supported by a
recent in vitro study in which the %DMA
was reduced from 53% in the normal cell line
Lindberg et al.
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Figure 2. The mean and confidence interval of the %MA by genotype of MTHFR A222V, MTHFR E429A,
GSTO1 A140D, and AS3MT M287T for (A) males and (B) females.
aHeterozygotes and homozygotes for the varient allele in the AS3MT polymorphism are combined. *p = 0.01. **p < 0.001.
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Table 3. Multiple regression analyses to test whether %DMA, %MA, and %iAs are dependent on sex, age, BMI, selenium, and some polymorphisms.
Age BMI Selenium MTHFR MTHFR GSTO1 GSTO1 As3MT (TC 
Sexa (years) (kg/m2) (µg/L) (CT vs. CC) (TT vs. CC) (CA vs. CC) (AA vs. CC) and CC vs. TT)
%DMA Bb 2.7* 0.021 0.36** –0.082** –0.57 –5.8** –0.23 2.4 –4.7**
No. = 374; R2 = 0.10 Betac 0.12* 0.021 0.15** –0.15** –0.025 –0.16** –0.010 0.063 –0.17**
%MA B –2.2** 0.036 –0.27** 0.080** 1.3 3.4* 0.061 –1.9 4.7**
No. = 374; R2 = 0.15 Beta –0.14** 0.051 –0.16** 0.21** 0.079 0.13* 0.0037 –0.071 0.23**
ln %iAs B –0.15* –0.0053 –0.011 –0.000081 –0.017 0.20 –0.0075 0.012 0.061
No. = 347; R2 = 0.02  Beta –0.11* –0.094 –0.083 –0.0027 –0.013 0.10 (p = 0.08) –0.0058 0.0057 0.038
aMale = 0; female = 1. bUnstandardized regression coefﬁcient. cStandardized regression coefﬁcient. *p < 0.05. **p < 0.01.to 11% in the cell line with silenced AS3MT
expression (Drobna et al. 2006). Interestingly,
we found that the M287T (C→T) poly-
morphism in AS3MT was not as important in
women as it was in men, who also had higher
%MA than women. 
Also, the A222V (C→T) polymorphism in
the MTHFR gene was associated with higher
%MA. MTHFR reduces methylenetetra-
hydrofolate to methyltetrahydrofolate, which
regenerates methionine from homocysteine in
the one-carbon metabolism with methylated
vitamin B12 as co-factor (Figure 1). The
A222V (C→T) polymorphism has been asso-
ciated with reduced enzyme activity and ele-
vated levels of homocysteine (Baum et al.
2004), which in turn could lead to lower
SAM-dependent methylation via feedback
inhibition, possibly explaining our results. An
interesting finding in the present study was
that mutation on only one allele was needed
to alter the arsenic metabolite pattern in
males, whereas females needed mutations on
both alleles. This discrepancy could be because
females have a generally higher rate of
remethylation of methionine from homo-
cysteine than do males (Fukagawa et al. 2000).
Furthermore, the influence of the A222V
polymorphism on the metabolite pattern was
more pronounced in individuals > 60 years of
age (data not shown). The elderly are known
to have poorer nutrition, especially lower vita-
min B12 levels, than younger people (Martin
2006), which could make them more suscepti-
ble to the reduced enzyme activity that might
result from the polymorphism.
Marnell et al. (2003) observed that two
individuals with an uncommon genotype of
GSTO1 had an altered distribution of iAs
metabolites in urine. However, studies with
GSTO1 knockout mice showed that they still
reduced arsenic(V) species, but to a lesser
extent (~ 20% of that found in wild-type
mice) (Chowdhury et al. 2006). This animal
study supports our finding that poly-
morphisms in GSTO1 are not associated with
an altered arsenic metabolite pattern, indicat-
ing nonenzymatic reduction and/or the
presence of alternative enzymes for these
reduction reactions. 
Several studies have shown associations
between malnourishment and increased risk
for different arsenic induced health effects,
partly due to less antioxidant defense and
partly due to alterations in the metabolism of
arsenic (Gamble et al. 2005; Milton et al.
2004; Mitra et al. 2004; Steinmaus et al.
2005). In the present study, we observed an
increase in %DMA and a decrease in %MA
and %iAs with increasing BMI. However, this
association was probably not due to nutritional
factors because most individuals were over-
weight (median BMI, 27 kg/m2). The BMI-
related difference in methylation was mainly
between normal-weight men and overweight
and obese women, and we found a difference
between the sexes in arsenic methylation only
in individuals < 60 years of age; therefore, the
results may suggest that sex steroids inﬂuence
the methylation of arsenic. Estrogen is pro-
duced in adipose tissue in both males and
females, leading to higher levels of estrogen in
overweight individuals (Nelson and Bulun
2001). Furthermore, sex hormone-binding
globulin is reduced with increasing body
weight, leading to the release of free estrogen
and progesterone (Pugeat et al. 1995).
However, more studies are needed on differ-
ences between the sexes and the inﬂuence of
sex steroids on the metabolism of arsenic.
Our hypothesis was that selenium would
increase the methylation capacity, as shown in
previous reports (Christian et al. 2006; Hsueh
et al. 2003). However, the present study indi-
cated the opposite association with selenium.
When further evaluation of the interaction
between selenium and BMI was performed, it
appeared that Romanians and Slovakians had
lower blood selenium but higher fractions of
methylated metabolites of arsenic in urine
compared with the Hungarians. Therefore,
the association between %DMA or %MA
and selenium was probably not a causal asso-
ciation, but rather an effect of, for example,
different food habits in the different coun-
tries. The selenium concentrations (mean ±
SD, 100 ± 22 μg/L) do not indicate defi-
ciency, and the concentrations were in the
same range as reported in several other
European populations (Batáriová et al. 2005;
Van Cauwenbergh et al. 1990). 
We were not able to confirm previous
ﬁndings that smoking and alcohol consump-
tion negatively influence the metabolism of
iAs (Hopenhayn-Rich et al. 1996; Hsueh et al.
2003). However, this was probably because of
the low arsenic exposure in the present study.
Because previous reports have shown the
presence of appreciable amounts of MA(III) in
human urine and have claimed that improper
sampling and storage conditions are likely rea-
sons for the absence of MA(III) in urine
(Feldmann et al. 1999), we also analyzed urine
samples from patients treated with high levels
of arsenic trioxide [30 mg arsenic/week (unpub-
lished data)]. Spot urine samples were collected
from four plasmacytoma patients both before
and after treatment and immediately frozen in
liquid nitrogen until analysis (~ 3 days after col-
lection). A trace amount of MA(III), too low to
be quantiﬁable, was found in one patient. The
results of the present study indicate that
MA(III) is not a significant metabolite in
human urine, in contrast to previous reports
(Aposhian et al. 2000; Le et al. 2000; Mandal
et al. 2001; Valenzuela et al. 2005). Our inter-
pretation is that the high reactivity renders
them to bind in tissue (Vahter 2002). 
In conclusion, the present study shows
that polymorphisms in genes coding for
enzymes involved in the metabolism of
iAs explains a part of the large interindividual
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Table 4. Multiple regression analyses separated by sex to test whether %DMA, %MA, and %iAs are
dependent on sex, BMI, selenium, and some polymorphisms.a
Selenium MTHFR MTHFR AS3MT (TC
No. R2 Ageb BMIc (µg/L) (CT vs. CC) (TT vs. CC) and CC vs. TT)
%DMA
Females 170 0.04 –0.015 0.072 –0.11 0.098 –0.20** –0.065
Males 204 0.12 0.094 0.13* –0.17** –0.13* –0.14* –0.25**
%MA
Females 170 0.04 0.12 –0.019 0.12 –0.049 0.14* 0.15*
Males 204 0.20 –0.039 –0.15** 0.27** 0.17** 0.11* 0.30**
ln %iAs
Females 158 0.008 –0.038 –0.098 0.046 –0.049 0.17** 0.0070
Males 189 0.009 –0.14* –0.10 –0.055 0.037 0.070 0.082
aStandardized regression coefﬁcients (β). bFor age < 60 years, 0; for age ≥ 60 years, 1. cFor BMI < 25 kg/m2, 0; for BMI
≥ 25 kg/m2, 1. *p < 0.10. **p < 0.05.
Figure 3. The mean and conﬁdence interval of %MA by age (A) and BMI (B) in males and females.
*p = 0.03.**p = 0.04.
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**variation seen in the metabolism of iAs,
especially in males, although not as much as
we hypothesized. Other methyltransferases are
probably backing up the methylation of
arsenic. Genes coding for enzymes involved in
the metabolism of iAs, as well as the inﬂuence
of polymorphisms in these genes on metabo-
lism, have only recently been investigated in
epidemiologic studies. More large-scale studies
are needed for complete understanding of
arsenic metabolism. 
REFERENCES
Aposhian HV, Zheng B, Aposhian MM, Le XC, Cebrian ME,
Cullen W, et al. 2000. DMPS–arsenic challenge test. II.
Modulation of arsenic species, including monomethyl-
arsonous acid (MMAIII), excreted in human urine. Toxicol
Appl Pharmacol 165:74–83.
Batáriová A, Cerná M, Spevacková V, Cejchanová M, Benes B,
Smíd J. 2005. Whole blood selenium content in healthy
adults in the Czech Republic. Sci Total Environ 338:183–188.
Baum L, Wong KS, Ng HK, Tomlinson B, Rainer TH, Chan DK,
et al. 2004. Methylenetetrahydrofolate reductase gene
A222V polymorphism and risk of ischemic stroke. Clin
Chem Lab Med 42:1370–1376.
Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, et al.
2003a. Arsenic methylation and skin cancer risk in south-
western Taiwan. J Occup Environ Med 45:241–248.
Chen YC, Su HJ, Guo YL Houseman EA, Christiani DC. 2005.
Interaction between environmental tobacco smoke and
arsenic methylation ability on the risk of bladder cancer.
Cancer Causes Control 16:75–81.
Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, et al.
2003b. Arsenic methylation and bladder cancer risk in
Taiwan. Cancer Causes Control 14:303–310.
Chowdhury UK, Zakharyan RA, Hernandez A, Avram MD,
Kopplin MJ, Aposhian HV. 2006. Glutathione-S-trans-
ferase-omega [MMA(V) reductase] knockout mice:
enzyme and arsenic species concentrations in tissues
after arsenate administration. Toxicol Appl Pharmacol
216:446–457.
Christian WJ, Hopenhayn C, Centeno JA, Todorov T. 2006.
Distribution of urinary selenium and arsenic among preg-
nant women exposed to arsenic in drinking water. Environ
Res 100:115–122.
Delnomdedieu M, Basti MM, Otvos JD, Thomas DJ. 1994a.
Reduction and binding of arsenate and dimethylarsinate
by glutathione: a magnetic resonance study. Chem Biol
Interact 90:139–155.
Delnomdedieu M, Basti MM, Styblo M, Otvos JD, Thomas DJ.
1994b. Complexation of arsenic species in rabbit erythro-
cytes. Chem Res Toxicol 7:621–627.
Del Razo LM, Garcia-Vargas GG, Vargas H, Albores A,
Gonsebatt ME, Montero R, et al. 1997. Altered proﬁle of uri-
nary arsenic metabolites in adults with chronic arsenicism.
A pilot study. Arch Toxicol 71:211–217.
Drobna Z, Xing W, Thomas DJ, Styblo M. 2006. shRNA silencing
of AS3MT expression minimizes arsenic methylation
capacity of HepG2 cells. Chem Res Toxicol 19:894–898.
DuBois D, DuBois EF. 1916. A formula to estimate the approxi-
mate surface area if height and weight be known. Arch
Intern Med 17:863–871.
Feldmann J, Lai VWM, Cullen WR, Ma M, Lu X, Le XC. 1999.
Sample preparation and storage can change arsenic
speciation in human urine. Clin Chem 45:1988–1997. 
Fukagawa NK, Martin JM, Wurthmann A, Prue, AH Ebenstein D,
O’Rourke B. 2000. Sex-related differences in methionine
metabolism and plasma homocysteine concentrations. Am
J Clin Nutr 72:22–29.
Gamble MV, Liu X, Ahsan H, Pilsner R, Ilievski V, Slavkovich V,
et al. 2005. Folate, homocysteine, and arsenic metabolism
in arsenic-exposed individuals in Bangladesh. Environ
Health Perspect 113:1683–1688.
Hayakawa T, Kobayashi Y, Cui X, Hirano S. 2005. A new metabolic
pathway of arsenite: arsenic-glutathione complexes are
substrates for human arsenic methyltransferase Cyt19. Arch
Toxicol 79:183–191.
Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE.
1996. Methylation study of a population environmentally
exposed to arsenic in drinking water. Environ Health
Perspect 104:620–628.
Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH,
et al. 1997. Serum beta-carotene level, arsenic methylation
capability, and incidence of skin cancer. Cancer Epidemiol
Biomarkers Prev 6:589–596.
Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL,
et al. 2003. Determinants of inorganic arsenic methylation
capability among residents of the Lanyang Basin, Taiwan:
arsenic and selenium exposure and alcohol consumption.
Toxicol Lett 137:49–63.
Hughes MF, Kenyon EM. 1998. Dose-dependent effects on the
disposition of monomethylarsonic acid and dimethyl-
arsinic acid in the mouse after intravenous administration.
J Toxicol Environ Health A 53:95–112.
Internal Agency for Research on Cancer. 2004. Some Drinking-
Water Disinfectants and Contaminants, including Arsenic.
IARC Monogr Eval Carcinog Risk Hum 84:1–512.
Kligerman AD, Tennant A. 2006. Insights into the carcinogenic
mode of action of arsenic. Toxicol Appl Pharmacol
doi:10.1016/j.taap.2006.10.006 [Online 13 October 2006].
Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. 2000.
Determination of monomethylarsonous acid, a key arsenic
methylation intermediate, in human urine. Environ Health
Perspect 108:1015–1018.
Lin S, Shi Q, Nix FB, Styblo M, Beck MA, Herbin-Davis KM,
et al. 2002. A novel S-adenosyl-L-methionine:arsenic(III)
methyltransferase from rat liver cytosol. J Biol Chem
277:10795–10803.
Lindberg AL, Goessler W, Gurzau E, Koppova K, Rudnai P,
Kumar R, et al. 2006. Arsenic exposure in Hungary, Romania
and Slovakia. J Environ Monit 8:203–208.
Maki-Paakkanen J, Kurttio P, Paldy A, Pekkanen J. 1998.
Association between the clastogenic effect in peripheral
lymphocytes and human exposure to arsenic through
drinking water. Environ Mol Mutagen 32:301–313.
Mandal BK, Ogra Y, Suzuki KT. 2001. Identiﬁcation of dimethy-
larsinous and monomethylarsonous acids in human urine
of the arsenic-affected areas in West Bengal, India. Chem
Res Toxicol 14:371–378.
Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA,
Walsh B, Avram MD, et al. 2003. Polymorphisms in the
human monomethylarsonic acid (MMAV) reductase/hGSTO1
gene and changes in urinary arsenic profiles. Chem Res
Toxicol 16:1507–1513.
Martin CM. 2006. Vitamins for the elderly: from A to zinc.
Consult Pharm 21:450–64.
Martin JL, McMillan FM. 2002. SAM (dependent) I AM: the
S-adenosylmethionine-dependent methyltransferase fold.
Curr Opin Struct Biol 12:783–793.
Meza MM, Yu L, Rodriguez YY, Guild M, Thompson D, Gandolf AJ,
et al. 2005. Developmentally restricted genetic determinants
of human arsenic metabolism: association between urinary
methylated arsenic and CYT19 polymorphisms in children.
Environ Health Perspect 113:775–781.
Milton AH, Hasan Z, Shahidullah SM, Sharmin S, Jakariya MD,
Rahman M, et al. 2004. Association between nutritional
status and arsenicosis due to chronic arsenic exposure in
Bangladesh. Int J Environ Health Res 14:99–108.
Mitra SR, Mazumder DN, Basu A, Block G, Haque R,
Samanta S, et al. 2004. Nutritional factors and susceptibility
to arsenic-caused skin lesions in West Bengal, India.
Environ Health Perspect 112:1104–1109.
Naranmandura H, Suzuki N, Suzuki KT. 2006. Trivalent arseni-
cals are bound to proteins during reductive methylation.
Chem Res Toxicol 19:1010–1018.
National Center for Biotechnology Information. 2007. Unigene.
Available: http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=unigene [accessed 27 February 2007].
National Research Council. 2001. Arsenic in Drinking Water,
2001 Update. Washington DC:National Academy Press.
Nelson LR, Bulun SE. 2001. Estrogen production and action. J Am
Acad Dermatol 45:S116–124.
Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV.
2000. Monomethylarsonous acid (MMAIII) is more toxic
than arsenite in Chang human hepatocytes. Toxicol Appl
Pharmacol 163:203–207.
PharmGKB. 2007a. Frequency of Variants at chr10:104628713 on
AS3MT. Available: http://www.pharmgkb.org/views/reports/
loadFrequencyInSampleSets.action?varRptId=126209365
[accessed 4 June 2007].
PharmGKB. 2007b. Frequency of Variants at chr10:106012779 on
GSTO1. Available: http://www.pharmgkb.org/views/reports/
loadFrequencyInSampleSets.action?varRptId=145825560
[accessed 4 June 2007].
PharmGKB. 2007c. Frequency of Variants at chr1:11790644 on
MTHFR. Available: http://www.pharmgkb.org/views/reports/
loadFrequencyInSampleSets.action?varRptId=127931865
[accessed 4 June 2007].
PharmGKB. 2007d. Frequency of Variants at chr1:11788742 on
MTHFR. Available: http://www.pharmgkb.org/views/reports/
loadFrequencyInSampleSets.action?varRptId=127932508
[accessed 4 June 2007].
Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC,
et al. 1995. Interrelations between sex hormone-binding
globulin (SHBG), plasma lipoproteins and cardiovascular
risk. J Steroid Biochem Mol Biol 53:567–572.
Schläwicke Engström K, Broberg K, Concha G, Nermell B,
Warholm M, Vahter M. 2006. Genetic polymorphisms inﬂu-
encing arsenic metabolism: evidence from Argentina.
Environ Health Perspect 115:599–605; doi:10.1289/ehp.9734
[Online 8 January 2007].
Schwerdtle T, Walter I, Hartwig A. 2003a. Arsenite and its bio-
methylated metabolites interfere with the formation and
repair of stable BPDE-induced DNA adducts in human cells
and impair XPAzf and Fpg. DNA Repair (Amst) 2:1449–1463.
Schwerdtle T, Walter I, Mackiw I, Hartwig A. 2003b. Induction of
oxidative DNA damage by arsenite and its trivalent and
pentavalent methylated metabolites in cultured human cells
and isolated DNA. Carcinogenesis 24:967–974.
Scott N, Hatlelid KM, MacKenzie NE, Carter DE. 1993. Reactions
of arsenic(III) and arsenic(V) species with glutathione.
Chem Res Toxicol 6:102–106.
Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA,
et al. 2006. Arsenic methylation and bladder cancer risk in
case-control studies in Argentina and the United States.
J Occup Environ Med 48:478–488.
Steinmaus C, Carrigan K, Kalman D, Atallah R, Yuan Y,
Smith AH. 2005. Dietary intake and arsenic methylation in
a U.S. population. Environ Health Perspect 113:1153–1159.
Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL,
Hamilton GA, et al. 2000. Comparative toxicity of trivalent
and pentavalent inorganic and methylated arsenicals in
rat and human cells. Arch Toxicol 74:289–299.
Thirumaran RK, Bermejo JL, Rudnai P, Gurzau E, Koppova K,
Goessler W, et al. 2006. Single nucleotide polymorphisms
in DNA repair genes and basal cell carcinoma of skin.
Carcinogenesis 27:1676–1681.
Vahter M. 1999. Variation in human metabolism of arsenic. In:
Arsenic Exposure and Health Effects III (Chappell WR,
Abernathy CO, Calderon RL, eds). Oxford, UK:Elsevier
Science Ltd., 267–279.
Vahter M. 2000. Genetic polymorphism in the biotransformation
of inorganic arsenic and its role in toxicity. Toxicol Lett
112–113:209–217.
Vahter M. 2002. Mechanisms of arsenic biotransformation.
Toxicology 181–182:211–217.
Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-
Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES,
et al. 2005. Urinary trivalent methylated arsenic species in
a population chronically exposed to inorganic arsenic.
Environ Health Perspect 113:250–254.
Van Cauwenbergh R, Robberecht H, Deelstra H. 1990. Selenium
concentration levels in whole blood of Belgian blood bank
donors, as determined by direct graphite furnace atomic
absorption spectrometry. J Trace Elem Electrolytes Health
Dis 4:215–224.
Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D.
2001. Differential effects of trivalent and pentavalent arseni-
cals on cell proliferation and cytokine secretion in normal
human epidermal keratinocytes. Toxicol Appl Pharmacol
172:225–232.
WHO. 2000. Obesity: Preventing and Managing the Global
Epidemic. WHO Technical Report Series 894. Geneva:World
Health Organization.
WHO. 2001. Arsenic and Arsenic Compounds. Environmental
Health Criteria 224. Geneva:World Health Organization.
Yu RC, Hsu KH, Chen CJ, Froines JR. 2000. Arsenic methylation
capacity and skin cancer. Cancer Epidemiol Biomarkers
Prev 9:1259–1262.
Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G,
Board PG, Liebler DC, et al. 2001. Human monomethylarsonic
acid (MMAV) reductase is a member of the glutathione-S-
transferase superfamily. Chem Res Toxicol 14:1051–1257.
1086 VOLUME 115 | NUMBER 7 | July 2007 • Environmental Health Perspectives
Lindberg et al.